购物车
- 全部删除
- 您的购物车当前为空
Iadademstat dihydrochloride (ORY-1001(trans)) 是一种不可逆的选择性赖氨酸特异性脱甲基酶 1A(KDM1A/LSD1) 抑制剂,用于治疗急性白血病。
为众多的药物研发团队赋能,
让新药发现更简单!
Iadademstat dihydrochloride (ORY-1001(trans)) 是一种不可逆的选择性赖氨酸特异性脱甲基酶 1A(KDM1A/LSD1) 抑制剂,用于治疗急性白血病。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 546 | 现货 | |
5 mg | ¥ 1,250 | 现货 | |
10 mg | ¥ 1,920 | 现货 | |
25 mg | ¥ 3,430 | 现货 | |
50 mg | ¥ 4,890 | 现货 | |
100 mg | ¥ 6,780 | 现货 | |
200 mg | ¥ 9,130 | 现货 |
产品描述 | Iadademstat dihydrochloride (ORY-1001(trans)) , a Potent and Selective Covalent KDM1A/LSD1 Inhibitor, for the Treatment of Acute Leukemia. |
体外活性 | ORY-1001 is a highly potent and selective KDM1A inhibitor that induces H3K4me2 accumulation on KDM1A target genes, blast differentiation, and reduction of leukemic stem cell capacity in AML. |
体内活性 | ORY-1001 exhibits potent synergy with standard-of-care drugs and selective epigenetic inhibitors, reduces growth of an AML xenograft model, and extends survival in a mouse PDX (patient-derived xenograft) model of T cell acute leukemia.?Surrogate pharmacodynamic biomarkers developed based on expression changes in leukemia cell lines were translated to samples from patients treated with ORY-1001.?ORY-1001 is a selective KDM1A inhibitor in clinical trials and is currently being evaluated in patients with leukemia and solid tumors. |
别名 | ORY-1001(trans) |
分子量 | 303.27 |
分子式 | C15H24Cl2N2 |
CAS No. | 1431303-72-8 |
Smiles | Cl.Cl.N[C@H]1CC[C@@H](CC1)N[C@@H]1C[C@H]1c1ccccc1 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
溶解度信息 | DMSO: 3.03 mg/mL (10 mM) | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容